Biocartis raises EUR 30M, partners with Debiopharm

Diagnostic company Biocartis S.A. (Lausanne, Switzerland) raised EUR 30 million ($40.5 million) in a series B round. New investors Debiopharm S.A. (Lausanne, Switzerland) and Johnson & Johnson Development Corp. joined existing investors Aescap; Biovest; Advent Venture Partners; and Benaruca, the investment vehicle of Biocartis' founding director and CEO, Rudi Pauwels. Several company employees also participated. Aescap's Dinko Valerio, a director on Biocartis' board, becomes chairman. Debiopharm's Pietro Scalfaro also joins the board. ...